Immunovant, Inc. Form 10-Q Summary
Reporting period: Three months ended June 30, 2021, Immunovant’s fiscal first quarter of 2022. The filing was signed August 9, 2021. Immunovant is a clinical-stage biopharmaceutical company developing IMVT-1401, a fully human anti-FcRn antibody for autoimmune diseases. The company has one operating segment and has not generated product revenue.
Financial performance and position
| Metric | Three months ended June 30, 2021 | Three months ended June 30, 2020 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $18.7 million | $16.9 million | +$1.8 million |
| General and administrative expense | $11.2 million | $9.7 million | +$1.5 million |
| Total operating expenses | $29.9 million | $26.6 million | +$3.3 million |
| Net loss | $30.5 million | $26.7 million | Loss increased by $3.8 million |
| Basic and diluted net loss per share | $0.31 loss | $0.38 loss | Improved per share, partly due to higher share count |
| Net cash used in operating activities | $21.2 million | $13.8 million | Use increased by $7.4 million |
- Cash and liquidity: Cash was $379.0 million at June 30, 2021, down from $400.1 million at March 31, 2021. Management expected existing cash to fund operating expenses and capital expenditures for at least the next 12 months from the filing date.
- Assets and liabilities: Total assets were $388.0 million, total liabilities were $22.5 million, and stockholders’ equity was $365.5 million. The filing reports no debt outstanding; liabilities primarily consisted of accounts payable, accrued expenses, and operating lease liabilities.
- Accumulated deficit: $229.1 million at June 30, 2021.
- Cash flow detail: Financing activities provided only $0.1 million during the quarter, compared with $193.6 million in the prior-year period from equity issuance and warrant redemptions. Investing cash use was $0.02 million.
- Margins: Operating and net margins are not meaningful because the company had no revenue and recorded operating losses.
- Stock-based compensation: $3.8 million was recognized in operating expenses during the quarter, primarily in general and administrative expense.
Material changes versus the prior comparable period
- Research and development expense increased 11%, principally because of higher personnel-related costs and other clinical-study and clinical-research costs. Contract manufacturing expense declined because clinical dosing had been paused.
- General and administrative expense increased 16%, primarily due to higher headcount and related personnel costs.
- Net loss increased 14% to $30.5 million, while weighted-average shares outstanding increased from 70.8 million to 98.0 million. The higher share count caused reported loss per share to improve despite the larger total loss.
- Operating cash burn increased to $21.2 million from $13.8 million.
- Unlike the prior-year quarter, there was no significant equity financing activity during the reported quarter.
Clinical program, outlook, and risks
- All company clinical dosing of IMVT-1401 was voluntarily paused in February 2021 after dose-dependent increases in total cholesterol and LDL levels were observed, together with dose-dependent albumin reductions. No major adverse cardiovascular events had been reported in the company’s trials as of the filing.
- The company completed a program-wide clinical and nonclinical data review from February through May 2021 and intended to resume development across multiple indications, subject to regulatory alignment and an acceptable risk-mitigation strategy.
- Management planned discussions with the FDA and other regulators during the second half of calendar 2021. The company expected an FDA meeting in early fourth quarter 2021 regarding modifications to the pivotal Phase 3 MG study and, contingent on FDA feedback, planned to initiate that study in early 2022.
- The ASCEND WAIHA study was expected to be reinitiated in the first half of 2022 if regulatory discussions were favorable. TED development was subject to further regulatory discussions because efficacy results from ASCEND GO-2 were inconclusive after the trial was terminated.
- In July 2021, the FDA granted orphan drug designation to batoclimab, the proposed non-proprietary name for IMVT-1401, for potential treatment of myasthenia gravis.
- On August 2, 2021, after quarter-end, the company issued 17,021,276 shares to Roivant Sciences Ltd. at $11.75 per share for gross proceeds of $200.0 million. The proceeds were intended to fund development of IMVT-1401 and general corporate purposes.
- Following the investment, Roivant beneficially owned approximately 63.8% of voting power as of August 9, 2021, increasing its control over stockholder and corporate matters.
- The company expects substantial future losses and additional capital needs. It had no committed external source of funds as of the filing, and future financing could dilute existing stockholders or impose restrictive terms.
- The HanAll license includes potential milestone payments of up to $442.5 million, reimbursement of up to $20.0 million of specified research and development costs, and tiered royalties ranging from the mid-single digits to mid-teens on net product sales.
- A putative securities class action filed in February 2021 alleges misleading statements regarding IMVT-1401 safety. The company has not accrued a liability because it could not reasonably estimate potential losses or determine whether an unfavorable outcome was probable.
- COVID-19 had not caused material financial effects through the filing date, although it had slowed clinical enrollment before the dosing pause and could affect future enrollment, supply chains, trial timelines, and financing access.
- The company reported effective disclosure controls as of June 30, 2021 and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether FDA and other regulatory discussions support a viable dosing and safety strategy addressing LDL elevations and albumin reductions.
- The timing, design, enrollment, and regulatory status of planned MG, WAIHA, and TED trials.
- Whether IMVT-1401 can demonstrate an acceptable long-term benefit-risk profile and meaningful efficacy after the clinical pause.
- Cash burn, remaining cash runway, and the effect of the $200.0 million post-quarter-end equity investment on funding needs and dilution.
- Potential HanAll milestone obligations, royalty economics, and the company’s ability to fund contingent payments before generating product revenue.
- Developments and potential financial exposure in the securities class action litigation.
- Roivant’s controlling ownership, related-party arrangements, and the resulting governance and minority-stockholder risks.